Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by Methyl-CpG binding proteins and histone modifications

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Müller, Imke ^a   Wischnewski, Frank ^a   Pantel, Klaus ^a   Schwarzenbach, Heidi ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLIN D2; DIMETHYL HISTONE 3 LYSINE 4; DIMETHYL HISTONE 3 LYSINE 9; GENOMIC DNA; GLIOMA PATHOGENESIS RELATED PROTEIN 1; HERMES ANTIGEN; HISTONE; HISTONE ANTIBODY; HISTONE H3; MBD1 ANTIBODY; MBD2 ANTIBODY; MESSENGER RNA; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 2; MONOMETHYL HISTONE 3 LYSINE 4; MONOMETHYL HISTONE 3 LYSINE 9; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REGULATOR PROTEIN; TRICHOSTATIN A; TRIMETHYL HISTONE 3 LYSINE 4; TRIMETHYL HISTONE 3 LYSINE 9; UNCLASSIFIED DRUG; CCND2 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; ENZYME INHIBITOR; GLIPR1 PROTEIN, HUMAN; NERVE PROTEIN; PTEN PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL SPECIFICITY; CELL STRAIN MCF 7; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; EMBRYO; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; BREAST TUMOR; CPG ISLAND; DRUG EFFECT; FEMALE; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANTIGENS, CD44; BREAST NEOPLASMS; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CPG ISLANDS; CYCLIN D2; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONES; HUMANS; MALE; METHYL-CPG-BINDING PROTEIN 2; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 77953555473     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-297     Document Type: Article

References (40)

1. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006, 31(2):89-97. 10.1016/j.tibs.2005.12.008, 16403636.
2. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002, 196(1):1-7. 10.1002/path.1024, 11748635.
3. Hendrich B, Tweedie S. The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet 2003, 19(5):269-277. 10.1016/S0168-9525(03)00080-5, 12711219.
4. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 1998, 18(11):6538-6547. 109239, 9774669.
5. Kondo E, Gu Z, Horii A, Fukushige S. The thymine DNA glycosylase MBD4 represses transcription and is associated with methylated p16(INK4a) and hMLH1 genes. Mol Cell Biol 2005, 25(11):4388-4396. 10.1128/MCB.25.11.4388-4396.2005, 1140624, 15899845.
6. Jorgensen HF, Ben-Porath I, Bird AP. Mbd1 is recruited to both methylated and nonmethylated CpGs via distinct DNA binding domains. Mol Cell Biol 2004, 24(8):3387-3395. 10.1128/MCB.24.8.3387-3395.2004, 381685, 15060159.
7. Wischnewski F, Friese O, Pantel K, Schwarzenbach H. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res 2007, 5(7):749-759. 10.1158/1541-7786.MCR-06-0364, 17634428.
8. Yu F, Zingler N, Schumann G, Stratling WH. Methyl-CpG-binding protein 2 represses LINE-1 expression and retrotransposition but not Alu transcription. Nucleic Acids Res 2001, 29(21):4493-4501. 10.1093/nar/29.21.4493, 60185, 11691937.
9. Fujita H, Fujii R, Aratani S, Amano T, Fukamizu A, Nakajima T. Antithetic effects of MBD2a on gene regulation. Mol Cell Biol 2003, 23(8):2645-2657. 10.1128/MCB.23.8.2645-2657.2003, 152551, 12665568.
10. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, Tempst P, Reinberg D, Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 1999, 23(1):58-61. 10.1038/12659, 10471499.
11. Zheng YG, Wu J, Chen Z, Goodman M. Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy. Med Res Rev 2008, 28(5):645-87. 10.1002/med.20120, 18271058.
12. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004, 4(6):448-456. 10.1038/nrc1370, 15170447.
13. Isacke CM, Yarwood H. The hyaluronan receptor, CD44. Int J Biochem Cell Biol 2002, 34(7):718-721. 10.1016/S1357-2725(01)00166-2, 11950588.
14. Peng ST, Su CH, Kuo CC, Shaw CF, Wang HS. CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. Int J Oncol 2007, 31(5):1119-1126.
15. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
16. Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006, 66(21):10233-10237. 10.1158/0008-5472.CAN-06-1464, 17079438.
17. Kito H, Suzuki H, Ichikawa T, Sekita N, Kamiya N, Akakura K, Igarashi T, Nakayama T, Watanabe M, Harigaya K, et al. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate 2001, 49(2):110-115. 10.1002/pros.1124, 11582589.
18. Verkaik NS, van Steenbrugge GJ, van Weerden WM, Bussemakers MJ, van der Kwast TH. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab Invest 2000, 80(8):1291-1298. 10.1038/labinvest.3780137, 10950120.
19. Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 2007, 80(20):1873-1881. 10.1016/j.lfs.2007.02.026, 17383681.
20. Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jeronimo C. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med 2006, 84(11):911-918. 10.1007/s00109-006-0099-4, 17016690.
21. Rich T, Chen P, Furman F, Huynh N, Israel MA. RTVP-1, a novel human gene with sequence similarity to genes of diverse species, is expressed in tumor cell lines of glial but not neuronal origin. Gene 1996, 180(1-2):125-130. 10.1016/S0378-1119(96)00431-3, 8973356.
22. Rosenzweig T, Ziv-Av A, Xiang C, Lu W, Cazacu S, Taler D, Miller CG, Reich R, Shoshan Y, Anikster Y, et al. Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells. Cancer Res 2006, 66(8):4139-4148. 10.1158/0008-5472.CAN-05-2851, 16618735.
23. Ren LLC, Yang G, Timme TL, Goltsov A, Ren C, Ji X, Addai J, Luo H, Ittmann MM, Thompson TC. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res 2004, 64(3):969-976. 10.1158/0008-5472.CAN-03-2592, 14871827.
24. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007, 28(7):1379-1386. 10.1093/carcin/bgm052, 17341655.
25. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007, 26(9):1338-1345. 10.1038/sj.onc.1210202, 17322919.
26. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005, 24(50):7465-7474. 10.1038/sj.onc.1209096, 16288293.
27. Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, Tamura Y, Satone A, Ide W, Hashimoto I, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol 2001, 18(2):109-114. 10.1007/BF02479423, 11908866.
28. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol 2008, 20(6):705-710. 10.1097/CCO.0b013e328313699c, 18841054.
29. Lopez-Serra L, Ballestar E, Fraga MF, Alaminos M, Setien F, Esteller M. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res 2006, 66(17):8342-8346. 10.1158/0008-5472.CAN-06-1932, 16951140.
30. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, Cigudosa JC, Huang TH, Esteller M. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. Embo J 2003, 22(23):6335-6345. 10.1093/emboj/cdg604, 291845, 14633992.
31. Dahl JA, Collas P. Q2ChIP, a quick and quantitative chromatin immunoprecipitation assay, unravels epigenetic dynamics of developmentally regulated genes in human carcinoma cells. Stem Cells 2007, 25(4):1037-1046. 10.1634/stemcells.2006-0430, 17272500.
32. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129(4):823-837. 10.1016/j.cell.2007.05.009, 17512414.
33. Squazzo SL, O'Geen H, Komashko VM, Krig SR, Jin VX, Jang SW, Margueron R, Reinberg D, Green R, Farnham PJ. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res 2006, 16(7):890-900. 10.1101/gr.5306606, 1484456, 16751344.
34. Nguyen CT, Gonzales FA, Jones PA. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res 2001, 29(22):4598-4606. 10.1093/nar/29.22.4598, 92514, 11713309.
35. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000, 403(6765):41-45. 10.1038/47412, 10638745.
36. El-Osta A, Kantharidis P, Zalcberg JR, Wolffe AP. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 2002, 22(6):1844-1857. 10.1128/MCB.22.6.1844-1857.2002, 135609, 11865062.
37. Radhakrishnan P, Basma H, Klinkebiel D, Christman J, Cheng PW. Cell type-specific activation of the cytomegalovirus promoter by dimethylsulfoxide and 5-Aza-2'-deoxycytidine. Int J Biochem Cell Biol 2008, 40(9):1944-55. 10.1016/j.biocel.2008.02.014, 18373939.
38. Pryzbylkowski P, Obajimi O, Keen JC. Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res Treat 2008, 111(1):15-25. 10.1007/s10549-007-9751-0, 17891453.
39. Krishnan M, Singh AB, Smith JJ, Sharma A, Chen X, Eschrich S, Yeatman TJ, Beauchamp RD, Dhawan P. HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene 29(2):305-312. 10.1038/onc.2009.324, 19881542.
40. Hirsch CL, Bonham K. Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells. FEBS Lett 2004, 570(1-3):37-40. 10.1016/j.febslet.2004.06.018, 15251435.